Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029

Design Therapeutics, Inc.

Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.
Cash, equivalents and securities $219.8M as of Dec 31, 2025; runway into 2029.
DT-216P2 (FA) RESTORE-FA trial ongoing; frataxin data expected H2 2026.
DT-168 (FECD) Phase 2 biomarker trial data anticipated H2 2026.
DT-818 (DM1) Phase 1 MAD trial dosing expected H1 2026; results in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.